Each year, an estimated 55,000 to 60,000 bone marrow or umbilical cord blood transplants (also called hematopoietic cell transplants) are performed worldwide to treat patients with life-threatening diseases.  Due to advances in transplantation, long-term experience and ongoing clinical trials, doctors can now recommend transplant to more patients than ever before. The list of diseases for which a transplant is a standard treatment option continues to grow.
Below is a list of diseases for which a transplant — either autologous (using the patient’s own cells) or allogeneic (using a donor’s cells) — may be a treatment. The list includes diagnoses for which transplant is a standard treatment as well as those for which it is a newer option.
Leukemias and lymphomas, including:
- Acute myelogenous leukemia
- Acute lymphoblastic leukemia
- Chronic myelogenous leukemia
- Chronic lymphocytic leukemia
- Juvenile myelomonocytic leukemia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
Learn more about research advancing treatments for acute leukemias
Multiple myeloma and other plasma cell disorders
Severe aplastic anemia and other marrow failure states, including:
SCID and other inherited immune system disorders, including:
- Severe combined immunodeficiency (SCID, all sub-types)
- Wiskott-Aldrich syndrome
- Beta thalassemia major
- Sickle cell disease
Hurler's syndrome and other inherited metabolic disorders, including:
- Hurler's syndrome (MPS-IH)
- Metachromatic leukodystrophy
Myelodysplastic and myeloproliferative disorders, including:
- Refractory anemia (all types)
- Chronic myelomonocytic leukemia
- Agnogenic myeloid metaplasia (myelofibrosis)
Learn more about research advancing treatment for myelodysplastic disorders
Familial erythrophagocytic lymphohistiocytosis and other histiocytic disorders
Fine-tuning transplant for specific diseases
The most effective timing for transplant, pre-transplant conditioning regimen (chemotherapy and/or radiation), cell source and post-transplant treatment options vary by disease. Research targeted to specific diseases is ongoing and continues to improve patients’ survival rates and quality of life after transplant.
One way your funding helps
Be The Match Foundation® understands investing in cutting-edge research is critical to serving more patients in need of a transplant. Funding clinical and observational studies is costly. But the data gleaned from in-depth patient tracking is so vital to refining therapies, improving survival rates and discovering the next generation of transplant care that your funds are needed here.
You have the power to heal. Please give to support research.
Information for patients and families
To learn more about the symptoms, diagnosis and treatment options for many diseases treated with transplant, see information for patients.
Updates on current transplant research
- Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2010. Available at: www.cibmtr.org